Financings in Brief: Diametrics Medical
This article was originally published in The Gray Sheet
Executive Summary
Diametrics Medical: Raises $9.6 mil. in a private placement of 1.7 mil. shares of common stock for $5.50 per share. The shares will not be registered for a period of at least 180 days from the deal's closing. The $5.50 price is a 12% discount from the average closing price of the company's common for the 20 days before Jan. 26. St. Paul, Minnesota-based Diametrics says it will use the proceeds to expand its sales and marketing efforts, adding approximately ten direct U.S. sales reps by the end of 1995 to its current direct force of about 20. The company also plans to expand manufacturing capabilities by adding employees and automated equipment...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.